Aristotle Capital Boston, LLC released its “Small Cap Equity Fund” third-quarter 2025 investor letter, reporting strong results with the Russell 2000 Index hitting an all-time high. The fund (Class I-2) had a 3.16% return, underperforming the index’s 12.39% total return. Check out the top five holdings for more information on the fund’s best picks in 2025.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was highlighted in Aristotle Small Cap Equity Fund’s third-quarter 2025 investor letter. The biopharmaceutical company saw a one-month return of 8.74% and shares gained 39.09% over the last 52 weeks, closing at $49.28 on December 18, 2025, with a market cap of $2.826 billion.

Aristotle Small Cap Equity Fund praised Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in its investor letter, citing strong quarterly results, exceeding analyst expectations, and raising forecasts for fiscal year 2025. The company’s differentiated product pipeline and existing neurology products offer strong growth potential with attractive profitability and free cash flow generation.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is held in 29 hedge fund portfolios, up from 25 in the previous quarter. The company reported total revenue of $192.1 million in Q3 2025, compared to $175.7 million in Q3 2024. While acknowledging Supernus Pharmaceuticals’ potential, certain AI stocks may offer greater upside potential and less downside risk.

Read more at Yahoo Finance: Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3